bluebird bio Tender Offer Extended to May 2025
Deal News | Apr 16, 2025 | SK Capital
Carlyle, in collaboration with SK Capital Partners and Beacon Parent Holdings, has extended the expiration date of its tender offer to acquire all remaining shares of bluebird bio, now set to expire on May 2, 2025. This extension is due to the necessity of meeting remaining conditions, including regulatory approvals. Currently, 700,288 shares have been tendered. Bluebird bio, renowned in gene therapy, is positioned as a leader in addressing genetic diseases. Carlyle, a firm managing $441 billion in assets, and SK Capital, boasting a $9 billion portfolio, are working together to transition bluebird bio under their ownership. The transaction represents a significant move in the biotech space, underscoring the strategic importance of gene therapy.
Sectors
- Biotechnology
- Private Equity
- Investment Management
Geography
- United States – bluebird bio, Carlyle, SK Capital, and Beacon Parent Holdings are based in the U.S., making it the primary geographic focus of this transaction.
Industry
- Biotechnology – bluebird bio operates within the biotechnology sector, focusing on developing gene therapies for genetic diseases.
- Private Equity – Carlyle and SK Capital are prominent players in the private equity industry, specializing in acquiring and managing stakes in various companies.
- Investment Management – Carlyle and SK Capital are involved in investment management, overseeing extensive portfolios across different sectors.
Financials
- $700,288 – The number of shares of bluebird bio common stock validly tendered as of April 15, 2025.
- $441 billion – Carlyle's assets under management as of December 31, 2024.
- $9 billion – Assets under management by SK Capital.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| bluebird bio, Inc. | Target Company | Company | A biotechnology company specializing in gene therapies for severe genetic diseases. |
| Carlyle | Bidding Company | Company | A global investment firm managing $441 billion in assets, focusing on private equity, credit, and investment solutions. |
| SK Capital Partners, LP | Bidding Company | Company | A private investment firm focusing on the life sciences and specialty materials sectors, managing $9 billion in assets. |
| Beacon Parent Holdings, L.P. | Bidding Company | Company | Part of the consortium extending the tender offer for bluebird bio. |
| Beacon Merger Sub, Inc. | Acquisition Vehicle | Company | A legal entity formed to facilitate the acquisition of bluebird bio. |
| Equiniti Trust Company, LLC | Depository | Company | The depositary managing the tendered shares of bluebird bio for the offer. |